Showing results (41-50 of 78) with videos related to

Sort By:
Pageof 8
Targeted Oncology|March 31, 2019
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting SystemEmanuel Raschi, Alessandra Mazzarella, Ippazio Cosimo Antonazzo, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 15, 2024
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance DatabasePaola Maria Cutroneo, Elena Arzenton, Fabiana Furci, et al.
Expert Review of Vaccines|February 18, 2018
No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and vigibaseCarla Carnovale, Emanuel Raschi, Luca Leonardi, et al.
Drug Safety|September 27, 2014
Safety profile of biological medicines as compared with non-biologicals: an analysis of the italian spontaneous reporting system databasePaola M Cutroneo, Valentina Isgrò, Alessandra Russo, et al.
Aging Clinical and Experimental Research|April 7, 2025
Safety of direct oral anticoagulants reversal agents in older patients: an analysis of individual case safety reports of adverse drug reaction from VigiBase®Giada Crescioli, Niccolò Lombardi, Elena Arzenton, et al.
European Journal of Clinical Pharmacology|March 6, 2014
Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluationFrancesco Salvo, Emanuel Raschi, Ugo Moretti, et al.
Frontiers in Drug Safety and Regulation|September 22, 2025
Conducting and interpreting disproportionality analyses derived from spontaneous reporting systemsPaola Maria Cutroneo, Daniele Sartori, Marco Tuccori, et al.
Drug Safety|May 9, 2024
Antipsychotic-Related DRESS Syndrome: Analysis of Individual Case Safety Reports of the WHO Pharmacovigilance DatabaseRenato de Filippis, John M Kane, Elena Arzenton, et al.
Plos One|November 27, 2013
Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across EuropeEmanuel Raschi, Elisabetta Poluzzi, Brian Godman, et al.
Drug Safety|November 18, 2022
Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting DatabaseChiara Gastaldon, Georgios Schoretsanitis, Elena Arzenton, et al.
Pageof 8